

EUROPEAN CDMO PARTNER AND API MANUFACTURER SINCE 1951

NEARLY 70 YEARS OF EXPERIENCE IN PROCESS
DEVELOPMENT AND COMMERCIAL PRODUCTION OF
ACTIVE INGREDIENTS

PRODUCTION CAPACITY AND COMPETENCES,
FDA-APPROVED SITE INTEGRATING R&D,
PILOT AND LARGE SCALE COMMERCIAL PLANTS

DEVELOPMENT AND MANUFACTURING SERVICES
FROM EARLY CLINICAL PHASES TO FULL LIFE
CYCLE MANAGEMENT

STRATEGIC INVESTMENT IN HP API AND
CRYOGENIC TECHNOLOGIES

> 50 

> 60 

MORE THAN 50 APIS ACTIVELY SOLD
GLOBALLY IN MORE THAN
60 OF THE BIGGEST MARKETS
ON 6 CONTINENTS

CONTACT US

API SALES

@ api@polpharma.com
api.polpharma.com
ipochem.com.pl

CDMO

@ cdmo@polpharma.com
cdmo.api.polpharma.com

Technical Customer Support

techCS.API@polpharma.com

MEET US

LinkedIn

<https://www.linkedin.com/showcase/polpharma-api/>

POLPHARMA

Pelplinska 19
83-200 Starogard Gdanski
Poland
+48 58 563 16 00

IPOCHEM

Annopol 6
03-236 Warsaw
Poland
+48 22 519 47 40

Last update: November 2022



API

PRODUCT LIST

API PRODUCT LIST

	PRODUCT	Therapeutic Category	Polymorphic form	CAS No.	EU DMF	CEP	US DMF	CHINESE DMF	JAPANESE DMF	KOREAN DMF	CANADIAN DMF	BRASILIAN DMF
1.	Acenocumaryl*	Cardiovascular system		152-72-7	●							
2.	Acetazolamide	Cardiovascular system	Form II	59-66-5	●	●	●			●		
3.	Alendronate sodium	Musculo-skeletal system	Trihydrate	121268-17-5	●	●	●		●	●	●	
4.	Aniracetam	Nervous system	Monoclinic form	72432-10-1	●							
5.	Aripiprazole	Nervous system	Type I	129722-12-9	●	●	●					
6.	Aripiprazole monohydrate (non-sterile)	Nervous system	Monohydrate	851220-85-4	●		●					
7.	Baclofen	Musculo-skeletal system	Form B	1134-47-0	●	●	●		●	●	●	●
8.	Carbamazepine	Nervous system	Form III	298-46-4	●	●	●			●		
9.	Carvedilol	Cardiovascular system	Form II	72956-09-3	●	●	●		●	●		
10.	Carvedilol phosphate hemihydrate	Cardiovascular system	Form I	610309-89-2	●		●					
11.	Clopidamide*	Cardiovascular system	Polymorphic form	636-54-4	●							
12.	Etodolac	Musculo-skeletal system	Crystalline racemate, none	41340-25-4	●	●	●		●	●	●	●
13.	Hydrochlorothiazide	Cardiovascular system	Form I	58-93-5	●	●	●	●	●	●	●	●
14.	Ibandronate sodium	Musculo-skeletal system	Monohydrate Form B	138926-19-9	●	pending	●	●	●	●		pending
15.	Lamotrigine	Nervous system	Anhydrous monoclinic	84057-84-1	●	●	●	●	●	●		
16.	Nefopam Hydrochloride*	Nervous system		23327-57-3	●							
17.	Opipramol dihydrochloride	Nervous system	Amorphous	909-39-7	●							
18.	Oxcarbazepine	Nervous system	Form A	28721-07-5	●	pending	●					
19.	Pentoxifylline	Cardiovascular system	Form I	1677687	●	●	●	●				
20.	Phenyl salicylate	Antipyretic, analgesic and anti-inflammatory	Crystalline orthorhombic form	118-55-8	●							
21.	Piracetam	Nervous system	Form II	7491-74-9	●	●						●
22.	R-Baclofen	Musculo-skeletal system	Form B	69308-37-8	●		●					
23.	R-Baclofen hydrochloride	Musculo-skeletal system	Crystalline HCl form	63701-55-3	●		●					
24.	Risedronate sodium	Musculo-skeletal system	Form A	115436-72-1	●	●	●		●	●	●	●

DISCLAIMER
Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in Germany or in countries where such products are subject to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer's responsibility and liability to check the patent situation of the product in the import market(s).

API PRODUCT LIST

	PRODUCT	Therapeutic Category	Polymorphic form	CAS No.	EU DMF	CEP	US DMF	CHINESE DMF	JAPANESE DMF	KOREAN DMF	CANADIAN DMF	BRASILIAN DMF
25.	Salicylamide	Antipyretic, analgesic and anti-inflammatory	Monoclinic form with space group 12/a	65-45-2	●							
26.	Sildenafil citrate	Genito-urinary system & sex horm	Anhydrous Form	171599-83-0	●	●	●	●	●		●	
27.	Sitagliptin hydrochloride	Alimentary tract & metabolism	Polymorphic form III	486459-71-6	●		●					
28.	Sodium salicylate	Antipyretic, analgesic and anti-inflammatory	Monoclinic form (space group P21/m)	54-21-7	●		●		●			
29.	Solifenacin succinate	Genito-urinary system & sex hormones	Form I	242478-37-1	●	●	●					
30.	Tadalafil	Genito-urinary system & sex hormones	Form A (form I)	171596-29-5	●	●	●	●	●			●
31.	Tolterodine tartrate	Genito-urinary system & sex hormones	Crystalline Form I	124937-52-6	●	●					●	
32.	Topiramate	Nervous system	Orthorhombic structure	97240-79-4	●		●			●		
33.	Vardenafil hydrochloride	Genito-urinary system & sex hormones	Trihydrate form	330808-88-3	●	●	●	●	●	●	●	●
34.	Xylometazoline HCl*	Respiratory system		1218-35-5	●	●						
35.	Zoledronic acid	Musculo-skeletal system	Monohydrate	165800-06-6	●	●	●		●		●	●

* IPOCHEM API manufacturing site

INJECTABLE GRADE

	PRODUCT	Therapeutic Category	Polymorphic form	CAS No.	EU DMF	CEP	US DMF	CHINESE DMF	JAPANESE DMF	KOREAN DMF	CANADIAN DMF	BRASILIAN DMF
1.	Acetazolamide	Cardiovascular system	Form II	59-66-5	●	●	●			●		
2.	Alendronate sodium	Musculo-skeletal system	Trihydrate	121268-17-5	●	●	●		●	●	●	
3.	Aripiprazole	Nervous system	Type I	129722-12-9	●	●	●					
4.	Baclofen	Musculo-skeletal system	Form B	1134-47-0	●	●	●		●	●	●	●
5.	Hydrochlorothiazide	Cardiovascular system	Form I	58-93-5	●	●	●	●	●	●	●	●
6.	Ibandronate sodium	Musculo-skeletal system	Monohydrate Form B	138926-19-9	●	pending	●	●	●	●		pending
7.	Pentoxifylline	Cardiovascular system	Form I	1677687	●	●	●	●				
8.	Piracetam	Nervous system	Form II	7491-74-9	●	●						●
9.	Risedronate sodium	Musculo-skeletal system	Form A	115436-72-1	●	●	●		●	●	●	●
10.	Zoledronic acid	Musculo-skeletal system	Monohydrate	165800-06-6	●	●	●		●		●	●

DISCLAIMER
Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in Germany or in countries where such products are subject to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer's responsibility and liability to check the patent situation of the product in the import market(s).

API PIPELINE

	PRODUCT	Therapeutic Category	Polymorphic form	CAS No.	EU DMF	CEP	US DMF	CHINESE DMF	JAPANESE DMF	KOREAN DMF	CANADIAN DMF	BRASILIAN DMF
1.	Apixaban	Blood & blood forming organs	Crystalline form N-1	503612-47-3	●			●			●	●
2.	Apremilast	Musculo-skeletal system	Form B	608141-41-9	●			●				
3.	Baricitinib	Antineoplastic & immunomodulating agents	Form I	1187594-09-7								
4.	Brexiprazole	Nervous system	Polymorphic form I	913611-97-9	●			●				
5.	Dapagliflozin	Alimentary tract & metabolism	Amorphous	461432-26-8	●			●		●	●	●
6.	Dapagliflozin Propanediol Monohydrate	Alimentary tract & metabolism	Crystalline SC-3	960404-48-2	●			●				
7.	Elagolix sodium	Genito-urinary system & sex hormones	Amorphous	832720-36-2	pending			pending				
8.	Empagliflozin	Alimentary tract & metabolism	Crystalline anhydrous	864070-44-0	●			●	●		●	
9.	Enzalutamide	Oncology	Anhydrous form R1	915087-33-1								
10.	Isavuconazonium sulfate	Antifungal agent	Amorphous	742049-41-8								
11.	Linagliptin	Alimentary tract & metabolism	Form: mix A&B	668270-12-0	●			●	●		●	●
12.	Pimavanserin tartrate	Nervous system	Crystalline anhydrous form C	389574-19-0	●			●				
13.	Rivaroxaban	Blood & blood forming organs	Modification I	366789-02-8	●			●	●		●	
14.	Sacubitril/Valsartan complex	Cardiovascular system	Crystalline	171599-83-0	●			●				
15.	Safinamide methanesulfonate	Nervous system	Crystalline anhydrous form A1	202825-46-5	●			●				
16.	Ticagrelor	Blood & blood forming organs	Form II	274693-27-5	●	pending		●			●	●

DISCLAIMER
Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in Germany or in countries where such products are subject to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer's responsibility and liability to check the patent situation of the product in the import market(s). Based on exemption under art. 5(2) of the Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products Apixaban, Rivaroxaban and Ticagrelor, which are protected by SPCs in Poland, can be manufactured and offered only for the purpose of export to non-EU countries, provided all requirements of the Regulation are met.
No product of the above list is offered for sale or made available in Germany due to patent (SPC) protection.



WE PROVIDE

PROFESSIONAL SUPPORT IN AREAS
RELATED TO TECHNOLOGY,
ANALYTICAL AND SPECIAL
SERVICES

WE COLLABORATE

CLOSELY WITH YOU IN ORDER TO
SEARCH FOR AND SUGGEST SOLUTIONS
ON A DAY-TO-DAY BASIS WORKING IN
PARALLEL WITH YOUR TECHNICIANS AND
ANALYSTS TO OFFER THE BEST
SOLUTIONS ALONG THE WAY

WE SUPPORT

BY A TAILORED SOLUTIONS, ACCORDING
TO YOUR NEEDS IN ORDER TO HELP YOU
OVERCOME CHALLENGES DURING YOUR
FORMULATION DEVELOPMENT